Xie Fengjiao, Xiong Qin, Li Yilin, Yao Chengjiao, Wu Ruike, Wang Qiuxiang, Luo Lihong, Liu Hongling, Feng Peimin
Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
Evid Based Complement Alternat Med. 2022 Sep 15;2022:6275136. doi: 10.1155/2022/6275136. eCollection 2022.
Inflammatory bowel disease (IBD), also known as chronic nonspecific inflammatory disease of the colon and rectum, is primarily characterized by mucopurulent bloody stools, diarrhea, abdominal pain, and tenesmus. Its cause is uncertain. IBD patients frequently experience a high rate of recurrence, a protracted treatment course, and a high risk of carcinogenesis. Additionally, the difficulty of treatment is significantly increased by these illness characteristics. Currently, the normal treatment for this illness can lessen symptoms to some amount and even meet clinical treatment requirements, but due to serious side effects, unfavorable reactions, and high costs, we need to develop better complementary and alternative medicines. A number of studies have found that the imbalance of T helper cell 17 (Th17)/regulatory T cells (Treg) contributes significantly to the occurrence and progression of IBD and that Th17/Treg balance restoration is frequently useful in the management of IBD. As a result, regulating the Th17/Treg balance has also emerged as a novel approach to treating IBD. Traditional Chinese medicine (TCM) has gained popularity in recent years due to its advantages of low side effects, a variety of targets, and multiple regulatory mechanisms. A number of studies have shown that TCM can successfully intervene in the Th17/Treg imbalance and restore it, and research on the prevention and treatment of IBD by TCM by restoring Th17/Treg has also shown promising results. The characteristics of the Th17/Treg balance and its role in the pathogenesis of IBD, as well as the role of TCM in regulating the Th17/Treg imbalance, are analyzed. The research results are expected to provide a theoretical basis for the clinical treatment and pathology mechanism research of IBD.
炎症性肠病(IBD),又称结肠和直肠慢性非特异性炎症性疾病,主要特征为黏液脓血便、腹泻、腹痛和里急后重。其病因尚不明确。IBD患者经常复发率高、治疗疗程长且癌变风险高。此外,这些疾病特征显著增加了治疗难度。目前,这种疾病的常规治疗可以在一定程度上减轻症状,甚至满足临床治疗要求,但由于严重的副作用、不良反应和高昂的费用,我们需要开发更好的补充和替代药物。多项研究发现,辅助性T细胞17(Th17)/调节性T细胞(Treg)失衡在IBD的发生和发展中起重要作用,恢复Th17/Treg平衡通常对IBD的管理有用。因此,调节Th17/Treg平衡也已成为治疗IBD的一种新方法。近年来,中医因其副作用低、靶点多样和调节机制多重等优点而受到欢迎。多项研究表明,中医可以成功干预Th17/Treg失衡并使其恢复,通过恢复Th17/Treg对IBD进行防治的研究也显示出有希望的结果。分析了Th17/Treg平衡的特征及其在IBD发病机制中的作用,以及中医在调节Th17/Treg失衡中的作用。研究结果有望为IBD的临床治疗和病理机制研究提供理论依据。